Antonino Dimarco
Internal Medicine · Rome, NYNPI 1922002393
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 237 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,498 and has fallen 98.9% since, to $17 in 2025.
Across 237 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$553
- Novartis$549
- Novo Nordisk$449
- Lilly USA, LLC$345
- AstraZeneca$341
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$336
- plus $2K from 20 others
What the payments were for
- Food & beverage$4,18499%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 17 | $553 |
| Novartis | 30 | $549 |
| Novo Nordisk | 30 | $449 |
| Lilly USA, LLC | 22 | $345 |
| AstraZeneca | 23 | $341 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $336 |
| GSK | 19 | $314 |
| Boehringer Ingelheim | 10 | $181 |
| Abbott | 7 | $136 |
| Actelion Pharmaceuticals US, Inc. | 5 | $117 |
| Johnson & Johnson | 6 | $108 |
| Merck | 7 | $108 |
| Kowa Pharmaceuticals America, Inc. | 6 | $105 |
| Sanofi-aventis U.S. LLC | 5 | $92 |
| Mylan Specialty L.p. | 6 | $90 |
| Amarin Pharma, Inc. | 5 | $73 |
| Avanir Pharmaceuticals, Inc. | 4 | $55 |
| Dexcom, Inc. | 2 | $47 |
| Esperion Therapeutics, Inc. | 2 | $42 |
| Grifols USA, LLC | 2 | $38 |
| Pfizer | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 1 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| United Therapeutics Corporation | 1 | $22 |
| Medicomp Inc | 1 | $12 |
| Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,213 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 16 | $234 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Rome
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.